Comparing AMERIGROUP (AGP) & BioScrip (BIOS)
AMERIGROUP (NYSE: AGP) and BioScrip (NASDAQ:BIOS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Risk & Volatility
AMERIGROUP has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, BioScrip has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for AMERIGROUP and BioScrip, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioScrip has a consensus target price of $3.75, suggesting a potential upside of 44.79%. Given BioScrip’s higher probable upside, analysts clearly believe BioScrip is more favorable than AMERIGROUP.
This table compares AMERIGROUP and BioScrip’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
84.7% of BioScrip shares are held by institutional investors. 0.8% of BioScrip shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares AMERIGROUP and BioScrip’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioScrip||$935.59 million||0.35||-$41.50 million||($0.68)||-3.81|
AMERIGROUP has higher earnings, but lower revenue than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than AMERIGROUP, indicating that it is currently the more affordable of the two stocks.
BioScrip beats AMERIGROUP on 5 of the 9 factors compared between the two stocks.
AMERIGROUP Corporation is a multi-state managed healthcare company focused on serving people who receive healthcare benefits through publicly funded healthcare programs, including Medicaid, Children’s Health Insurance Program (CHIP), Medicaid expansion programs and Medicare Advantage. The Company offers a continuum of care management, including disease management, pharmacy integration, centralized telephonic case management, in-person case management within healthcare facilities, and home visit case management for some of its members. As of December 31, 2011, the Company provided a number of healthcare products to approximately 2,024,000 members. Effective February 1, 2012, it provides managed care services in Louisiana. On May 1, 2012, it acquired Health Plus. In November 2012, the Company sold its Virginia health plan to Inova Health System Foundation. In December 2012, WellPoint Inc acquired the Company.
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for AMERIGROUP Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMERIGROUP Co. and related companies with MarketBeat.com's FREE daily email newsletter.